Posted 16 August 2016
By Michael Mezher
The US Food and Drug Administration (FDA) has released a slew of warning letters—14 in total—sent from the Center for Devices and Radiological Health's (CDRH) Office of Compliance to five device manufacturers located in the UK, three in China, two in Germany, and one each in Argentina, France, Italy and the Philippines.
By far the most common issues cited by FDA were:
|Number of Citations||Issue|
Failure to establish and maintain adequate procedures for implementing corrective and preventative action (CAPA), as required by 21 CFR 820.100(a)
Failure to establish and maintain adequate procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a)
Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a)
Failure to establish and maintain procedures to ensure that all purchased or otherwise received products and services conform to specified requirements, as required by CFR 820.50
Additionally, nearly all of the warning letters (11 out of 14) cited the recipient for violating a subsection of 21 CFR 820.30, which requires manufacturers to establish and maintain procedures related to device design.
Medical device reporting was also cited as an issue in five of the warning letters, with FDA saying the companies failed to develop, maintain and implement medical device reporting requirements.
In four of the 14 warning letters, FDA says it did not review all or part of the companies' responses to their respective inspection observations because they were sent after the 15-day window in which FDA requires a response.